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Objectives: Non–small cell lung cancers commonly develop resistance to radiation
and chemotherapy, and they often present at stages beyond surgical resectability.
Because current treatment modalities are inadequate, novel therapies are necessary
to reduce the effects of the increasing incidence in pulmonary neoplasms. Fas-
associating death domain protein is a central mediator of death receptor–initiated
apoptosis that directly activates the caspase-8 protease. We hypothesized that
overexpression of Fas-associating death domain protein would effectively eradicate
lung cancer cells by induction of apoptosis.
Methods: Cultured A549 alveolar carcinoma and NCI-H226 squamous carcinoma
cells were exposed to increasing multiplicities of infection of a replication-deficient,
adenoviral vector that expresses the wild-type murine Fas-associating death domain
protein gene or control virus for 4 hours. Twenty-four hours later, cells were
assessed for viability by crystal violet staining and caspase activation by micro-
scopic analysis. Protein lysates were examined by Western blotting for expression
of Fas-associating death domain protein and activated caspase-8.
Results: Adenoviral infection with the wild-type murine Fas-associating death
domain protein gene in A549 cells resulted in a dose-dependent expression of
Fas-associating death domain protein and the appearance of cleaved, activated
caspase-8. Increasing multiplicities of infection of the wild-type murine Fas-asso-
ciating death domain protein gene, but not control adenovirus, was associated with
increased cell death in A549 and NCI-H226 cells. The wild-type murine Fas-
associating death domain protein gene infection of A549 cells at multiplicities of
infection of 50 induced at least 10-fold increase in Fas-associating death domain
protein levels and decreased viability by  50% (n  3; P  .001).
Conclusion: Overexpression of Fas-associating death domain protein induced dose-
dependent cell death in A549 and NCI-H226 lung epithelial cancer cells. Expression
of Fas-associating death domain protein results in activation of caspases, a hallmark
of apoptosis. Delivery of the wild-type murine Fas-associating death domain protein
gene to drug- and radiation-resistant lung cancer may be a novel method for therapy
of non-small cell lung cancer.
Lung cancer is the primary cause of malignancy-associated death inthe United States, with 170,000 new cases and 157,000 deathsestimated in 2001.1 Neither screening for early disease nor advancesin conventional cancer therapies have altered the 14% 5-year sur-vival rate of patients with non-small cell lung cancer. Therefore,further investigations are needed to identify new strategies for
treatment.
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Cellular death by the process of apoptosis is evident
morphologically by plasma membrane blebbing, cytoplas-
mic condensation, and fragmentation of cells and nuclei.2
Apoptosis can be induced with radiation, chemotherapeutic
agents, or oligomerization of death receptors by their re-
spective death ligands.3,4 Fas-associating death domain pro-
tein/mediator of receptor-induced toxicity (FADD/MORT1)
is a 29 kD cytoplasmic adaptor molecule that mediates
signal transduction pathways of apoptosis.5,6 When cells are
treated with death ligands that bind and activate death
receptors, FADD is recruited to the plasma membrane and
interacts with the intracellular death domain of death recep-
tors like Fas.7,8 FADD then oligomerizes the procaspase-8
zymogen and induces activation of caspase-8 by autocleav-
age.9,10 Activated caspase-8 can then cleave downstream
molecules that transmit and amplify the programmed cell
death signal.11
Because of the central role of FADD in activation of
apoptosis, we hypothesized that intracellular overexpression
of FADD would bypass death ligands and receptors to
induce caspase-8 activation and apoptosis. To prove this
hypothesis, an adenoviral vector that generates FADD pro-
tein was constructed and used to induce FADD overexpres-
sion in A549 and NCI-H226 lung carcinoma cells. The cells
were then assessed for apoptotic structure, cell viability, and
activation of caspases.
Materials and Methods
Cells and Reagents
A549 (alveolar cell carcinoma) and NCI-H226 (squamous cell
carcinoma) cells were obtained from the American Type Culture
Collection (Manassas, Va). A549 cells were maintained in media
containing F-12K Nutrient Mixture (Life Technologies, Carlsbad,
Calif), supplemented with penicillin (100 U/mL), streptomycin
(100 mg/mL), and 10% fetal bovine serum (v/v). NCI-H226 cells
were grown in RPMI-1640 media with 10% fetal bovine serum
(v/v), penicillin (100 U/mL), streptomycin (100 mg/mL), and
L-glutamine (1%). Antibodies used for this study were purchased
from Sigma Chemical Co (for -actin; St Louis, Mo), Stressgen
(for caspase-8; Victoria, BC, Canada), and Calbiochem (for
FADD; San Diego, Calif). BCA protein and Supersignal chemi-
luminescence detection reagents were from Pierce (Rockford, Ill).
Unless otherwise indicated, all other reagents were purchased from
Sigma Chemical Co.
Viral Vectors and Infection
Ad-FADD was constructed through Cre-lox recombination with
reagents provided by Dr S. Hardy (Somatix, Alameda, Calif). An
XhoI/XhoI 720 bp murine FADD cDNA coding region (isolated
from PCImMort1 FL; generously provided by Dr Astar Winoto)
was inserted into the shuttle vector pAdlox to create the Ad-FADD
expression vector. Ad-EGFP (enhanced green fluorescent protein)
was constructed and obtained as described previously12, and Ad-
Control (empty vector) was a gift from S. Hardy.
Cells were plated at 2  105 cells per well in 6-well dishes
for Western blotting and 5  104 cells per well in 12-well plates
for cell viability. For FADD gene transduction of A549
cells, Ad-FADD was added to cell cultures at increasing mul-
tiplicities of infection (MOI  number of PFU per cell) in
serum-free Opti-MEM (Gibco BRL, Rockville, Md). Cells were
incubated for 4 hours at 37°C and 5% CO2. Cells were washed
twice with phosphate-buffered saline solution (PBS) and fresh
media containing 10% serum was added. After 24 hours, cell
structure was photographed under phase-contrast light micros-
copy.
Immunoblotting Analysis
Cells were washed with cold PBS and removed from plates with
0.25% trypsin. Cells were resuspended in 5-fold volume of lysis
buffer containing 50 mmol/L Tris (pH 7.5), 150 mmol/L NaCl, 1
mmol/L ethylenediamine tetraacetic acid, 1% Triton X-100, 0.5
mmol/L phenylmethylsulfonyl fluoride, 5 g/mL aprotinin, 5
g/mL pepstatin, and 10 g/mL leupeptin. Lysates were incubated
at 4°C for 30 minutes, and cell debris was removed by centrifu-
gation at 13,000  g at 4°C for 15 minutes. The supernatant was
used for Western blotting analysis. Protein concentration was
determined with the BCA assay (Pierce) with bovine serum albu-
min as standard.
Forty micrograms of protein were separated on 13% SDS-
PAGE and transferred onto a nitrocellulose membrane. Loading of
equal protein amounts was assessed by staining of membranes
with 0.1% Ponceau S (Sigma Chemical Co) in 5% acetic acid.
Nonspecific binding was blocked with PBS-T (14 mmol/L sodium
phosphate, monobasic, monohydrate; 88 mmol/L dibasic sodium
phosphate, anhydrous; 100 mmol/L NaCl; and 0.1% Tween 20)
containing 5% nonfat milk for 1 hour incubation with agitation at
room temperature. Membranes were incubated with anti-FADD
(1:4000), anti-caspase-8 (1:1000), or anti--actin (1:1000) anti-
bodies for 1 hour and washed three times with PBS-T. The
horseradish peroxidase–conjugated goat antirabbit secondary an-
tibody (Amersham Pharmacia Biotech, Piscataway, NJ) was incu-
bated with membranes at 1:10,000 for 1 hour at room temperature.
After five washes with PBS-T, the protein bands were visualized
with Supersignal (Pierce) according to the manufacturer’s instruc-
tions. The bands were visualized on Kodak film (Eastman Kodak,
Rochester, NY) exposed to the membrane to detect chemilumines-
cence signals. Intensity of bands was assessed by densitometry
with UN-SCAN-IT (Silk Scientific, Orem, Utah).
Cell Viability Assays
Cell viability was determined by the crystal violet method as
described previously.13 Briefly, adherent cells were stained with
0.5% crystal violet in 30% ethanol and 3% formaldehyde for 10
minutes at room temperature. Plates were washed six times with
tap water. After drying, cells were lysed with 1% sodium dodecyl
sulfate solution, and dye uptake was measured at 550 nmol/L with
a 96-well microplate reader. Cell viability was calculated from
relative dye intensity of the mean for duplicate samples and
presented as percentages relative to untreated samples.
Caspase Activity Assay
Detection of activated caspases in NCI-H226 cells was performed
with the CaspaTag Pan-Caspase activity kit (Intergen Co, Pur-
chase, NY), following the manufacturer’s protocol. Briefly,
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caspase activation was detected using a fluorometric change upon
cleavage of a carboxyfluorescein-labeled fluoromethyl ketone-pep-
tide inhibitor (VAD). Nuclei were stained with Hoechst 33342.
Five hundred cells were visualized and counted in duplicate with
a triple bypass filter (Chroma 61002).
Statistical Analysis
Data are presented as means  standard error of the mean of three
separate experiments, except where results of blots are shown in
which case a representative experiment is depicted in the figure.
Comparisons between values were analyzed by one-way analysis
of variance (ANOVA) by use of the Student-Newman-Keuls
method with SigmaStat Statistical Software Version 2.03. Differ-
ences were considered significant at P  .05.
Results
FADD Expression in A549 Lung Cancer Cells
To estimate adenoviral infectivity of human lung cancer
cells, A549 cells were infected with Ad-EGFP (enhanced
green fluorescent protein) control virus. Greater than 90% of
A549 cells were fluorescent after infection with Ad-EGFP
at MOI 50, demonstrating efficient infectivity of these cells
(data not shown).
To assess whether the Ad-FADD vector could induce
expression of FADD protein in lung cancer cells, A549 cells
were infected with Ad-FADD in increasing concentrations
and harvested 24 hours later to assess FADD expression.
Western blotting was performed to demonstrate that infec-
tion with Ad-FADD resulted in a dose-dependent increase
in FADD expression in A549 lung cancer cells (Figure 1).
Ad-FADD at MOI of 50 induced greater than a 10-fold
increase in FADD expression. Actin levels were assessed to
confirm equal loading of protein in each lane.
Ad-FADD Infection and Dose-Dependent Apoptotic
Cell Death
To assess the structure of cells that overexpress FADD,
A549 cells infected with Ad-FADD were observed by
phase-contrast microscopy. Increasing doses of Ad-FADD
resulted in augmented numbers of cells with typical, apo-
ptotic morphology consisting of detached, condensed cells
with membrane blebbing (Figure 2). Control cells infected
with Ad-EGFP at MOI 50 (Figure 2, B) or no virus (Figure
2, A) displayed a minimal number of cells with apoptotic
structure.
To quantitate the cell death induced by Ad-FADD in
A549 cells, cell viability was measured for A549 cells after
infection with Ad-EGFP, no virus, or increasing concentra-
tions of Ad-FADD. Twenty-four hours later, cells were
fixed and stained with crystal violet, lysed, and quantitated
by spectrophotometry at 550 nm (Figure 3). Compared with
control, Ad-EGFP infection resulted in an insignificant de-
crease in cell viability (93.4  6.1%, n  3, P  .271).
However, Ad-FADD infection induced a dose-dependent
increase in cell death compared with Ad-EGFP infection.
Infection of A549 cells with Ad-FADD at MOI 10 showed
significant decrease in cell viability to 75.2  5.6% (n  3,
P  0.02). Ad-FADD treatments at MOI 25 and 50 resulted
in further decreases in cell viability to 57.1 5.8% and 47.7
 3.9%, respectively (n  3, P  .001).
Ad-FADD Treatment- and Concentration-Dependent
Caspase-8 Cleavage
Caspase-8, the most proximal initiator protease in the sig-
naling of apoptosis, exists as an inactive 55 kD zymogen
called procaspase-8 in cells that have not been stimulated to
undergo apoptosis.11 Treatment of cells with FasL results in
cleavage of procaspase-8 into multiple active forms, includ-
ing a 26-kD cleavage band that can be visualized by West-
ern blotting. To demonstrate that Ad-FADD treatment of
lung cancer cells would result in caspase-8 activation, A549
cells were exposed to increasing concentrations of Ad-
FADD, Ad-control virus, or no virus. Twenty-four hours
later, cells were harvested and the expression levels of
cleaved and uncleaved forms of caspase-8 were assessed by
Western blotting (Figure 4). Lysates of A549 cells from
control virus infection (lane 1, Ad-control at MOI 50) and
Figure 1. Dose-dependent FADD protein expression in lung cancer cells infected with Ad-FADD. A549 cells (2 
105) were plated in 6-well dishes and infected with increasing multiplicities of infection (MOI: 0, 5, 10, 25, and 50)
of Ad-FADD. Cells were harvested 24 hours later and protein lysates were probed by Western immunoblotting with
anti-FADD antibody. Membranes were stripped and reprobed with anti-actin antibody to demonstrate equal loading
of lanes.
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no virus treatment (lane 2) showed endogenous levels of
procaspase-8 with no expression of the cleaved, activated
fragment of caspase-8. In contrast, increasing concentra-
tions of Ad-FADD resulted in dose-dependent elevations in
active caspase-8, with corresponding reductions in expres-
sion of the procaspase-8 zymogen. The cleavage of
caspase-8 appeared to correlate with the increase in expres-
sion of FADD protein (Figure 1), apoptotic structure (Figure
2), and the decrease in cell viability (Figure 3) observed in
A549 cells infected with Ad-FADD.
Ad-FADD Infection-Induced Apoptotic Cell Death and
Caspase Activation in NCI-H226 Lung Cancer Cells
To demonstrate that the response to Ad-FADD was not
idiosyncratic to A549 cells, we treated the NCI-H226 lung
squamous carcinoma cell line with Ad-FADD. As in A549
cells, NCI-H226 cells infected with Ad-FADD induced cell
death with the characteristic structure of apoptosis, includ-
ing cytoplasmic condensation and plasma membrane bleb-
bing (Figure 5). Ad-FADD treatment reduced NCI-H226
viability from 100% to 64% by 24 hours after infection
(Figure 5). Control virus Ad-EGFP resulted in  90%
infectivity at MOI 50 (data not shown), but did not induce
significant cell death. Ad-FADD infection of NCI-H226
cells resulted in caspase activation (Figure 5, red) in a
significantly higher percentage of cells compared with con-
trols (Ad-FADD 18.8  5.0% versus mock virus 2.4 
0.3% versus media 1.8  0.4%, n  3, ANOVA P  .002).
Discussion
We have constructed a replication-deficient adenovirus that
expressed the FADD death gene in human lung cancer cells
and demonstrated that overexpression of FADD in A549
cells induced dose-dependent cell death with apoptotic
structure. The mechanism of this cell death involved cleav-
age of caspase-8, the most proximal initiator protease in the
signal transduction of apoptosis. This study proves our
hypothesis that without the addition of death receptor li-
gands or chemotherapeutic agents, overexpression of
FADD alone could induce apoptotic cell death in human
lung cancer cells.
Radiation and many chemotherapeutic agents induce ap-
optosis in susceptible cancer cells.4,14 Nevertheless, nonre-
sponders and recurrence of tumors are associated with drug-
resistant cancer clones.15,16 The induction of apoptosis by
ionizing radiation and chemotherapeutic drugs involves ei-
ther death receptor activation or, more commonly, p53-
dependent release of proapoptotic stimuli from mitochon-
dria that results in activation of caspase-9 (Figure 6).17,18
Significantly, these agents have been shown to induce apo-
ptosis in some cancer cells in the absence of FADD.19
However, in p53-deficient cells or cells that overexpress
Bcl-2, apoptosis could still be induced by Fas ligand. This
finding demonstrated that even when the mitochondrial
pathway of cell death was blocked in tumors, the Fas-FADD
pathway of cell death is still intact.19 Therefore, the thera-
peutic activation of FADD-dependent cell death pathways
may be useful to eradicate cancer cells resistant to radiation
or chemotherapy, or in conjunction with these modalities.
Unlike A549 cells, which are p53 wild type, NCI-H226
cells contain a missense mutation (R158L) in p53. Because
NCI-H226 cells were effectively killed by Ad-FADD (Fig-
ure 5), these studies suggest that Ad-FADD can induce
apoptosis by a p53-independent mechanism. Because mu-
tations in p53 are the most common mutation in human
cancer, overexpression of FADD may be a viable alternative
to other therapeutic modalities that require wild-type p53.
Induction of tumor cell death by overexpression of
FADD may have several therapeutic advantages.20 FADD is
an essential signaling molecule for apoptosis induced via
both Fas and tumor necrosis factor–related apoptosis-induc-
ing ligand (TRAIL) death receptors.8,21 A549 cells are
known to have decreased expression of cell surface Fas
death receptors and are resistant to apoptosis induced by
anti-Fas antibody.22 TRAIL is known to be cytotoxic to
A549 cells23 with some specificity to cancer cells.24 How-
ever, the cell surface expression of TRAIL death receptors
also has been discovered to be downregulated or mutated in
Figure 2. Structure of A549 cells treated with Ad-FADD infection.
Cells plated in 12 wells were infected with no virus (A), control
Ad-EGFP at MOI 50 (B), or Ad-FADD at increasing MOI of 5 (C), 10
(D), 25 (E), and 50 (F). Twenty-four hours after infection, cell
structure was photographed under phase-contrast microscopy at
original magnification  10.
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some cancer cells, which make them resistant to apoptosis
by death ligands.25,26 Inactive, decoy death receptors have
also been described in lung and colon cancers.27 In our
experiment, we have demonstrated that overexpression of
FADD results in caspase-8 activation without the addition
of FasL or TRAIL, effectively bypassing the need for func-
tional death receptors.
This study was performed to test our hypothesis that
overexpression of the FADD protein is a novel method to
induce apoptotic cell death in lung tumor cells. The major
drawback to these preliminary results includes the lack of
confirmation in an animal model of lung cancer. Intratu-
moral injections or endovascular delivery via a feeding
artery would be required to assess the ability of the Ad-
FADD vector to induce tumor cell death in vivo. However,
because adenoviral vectors are rapidly cleared by the im-
mune system, intratumoral injections of lung tumors may
not support any clinical advantage over other surgical or
systemic modalities unless a “bystander effect” can be in-
duced, as seen with gene therapy vectors that express wild-
type p53.28 Production of a cancer-specific vector29 that
encodes fadd would be necessary to assess intratumoral
FADD expression as a systemic, therapeutic approach that
could target lung neoplasms for unresectable or micrometa-
static disease. As an alternative to gene therapy, we have
demonstrated other modalities to increase endogenous
FADD expression in hepatocytes and keratinocytes that do
not involve viral vectors.30,31 Future research is also re-
quired to demonstrate whether lung cancer cell death by
overexpression of FADD may be enhanced in combination
with chemotherapy and radiation. Modulation of FADD
expression may be effective for lung cancer when other
modalities have failed, an all too common event experi-
enced in the therapeutic history of lung cancer.
Figure 3. Effect of Ad-FADD infection on A549 cell viability. A549 cells plated in 12 wells were exposed to no virus,
Ad-EGFP at MOI 50, or increasing concentrations of Ad-FADD (5, 10, 25, and 50). Twenty-four hours later, cell
viability was determined by crystal violet staining. Viability of control cells (no virus) was set at 100% and
viabilities relative to control are presented. Experiments were performed in duplicate for three experiments. Error
bars indicate standard error of the means. Significance was assessed with one-way ANOVA comparing the
viability after each Ad-FADD infection to the viability after Ad-EGFP infection at MOI 50 (n  3, *P  .02, **P <
.001).
Figure 4. Effect of Ad-FADD infection on procaspase-8 and activated caspase-8 cleavage protein levels. A549 cells
were plated in 6-well dishes and infected with increasing multiplicities of infection of Ad-FADD (MOI: 0, 5, 10, 25,
and 50), control empty virus (Ad-control) at MOI 50, or no virus. Cells were harvested 24 hours later and lysates
were probed by Western immunoblotting with anti-caspase-8 antibody.
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Discussion
Dr Frank W. Sellke (Boston, Mass). You showed pretty
clearly that you see increased activation of the caspases. Did you
look at something such as TUNEL assay to be sure that you are
actually seeing apoptosis rather than some inflammatory effect of
gene transfer or some other mechanism causing the cell death?
Dr Kim. There are a lot of assays for apoptosis, and actually in
our laboratory the results of TUNEL assay have been pretty
variable. Even though we can see apoptosis by structure and
activation or cleavage of caspases, we actually find with the
caspase stain that I showed that we have a better assessment that
caspases were indeed activated. Nevertheless, in these cell lines I
have not done any assessment of DNA fragmentation by DNA
laddering, TUNEL assay, or PARP cleavage.
Dr G. Alexander Patterson (St Louis, Mo). You acknowledge
some of the limitations of the study. There may be another limi-
tation. Is it correct that you studied two cell lines?
Dr Kim. Yes.
Dr Patterson. Do you have any comment about that and why
those particular cell lines were selected, or do you have any
preliminary data from other cell lines? In addition, I didn’t under-
stand exactly what the adenoviral control was and why you se-
lected that control versus some other control.
Dr Kim. I will answer the second question first. We have used
several controls. One would be an adenovirus that has no inserted
gene, and the control I showed was an adenovirus that overex-
presses the green fluorescent protein (Ad-EGFP). That is for two
reasons. When we look under a fluorescent microscope we see at
that dose (MOI 50) the adenovirus that overexpresses green fluo-
rescent protein. We can show that infectivity occurred in more than
90% of the cells. In terms of nonspecific cell death induced by
overexpressing any nonspecific protein, Ad-EGFP was the control
that we used. An empty adenovirus (Ad-control) is just a control
for nonspecific adenoviral toxicity.
As for the first question, we have actually done some prelim-
inary studies in other cell lines. We have looked at a couple of
adenocarcinoma cell lines, and we don’t see as much cell death as
we do in the squamous carcinoma cell lines; however, when you
look at the green fluorescent protein expression in adenocarcinoma
cells, there is less infectivity of those cells as well. So we are not
sure if the adenovirus is not getting into the cells to express the
FADD protein as an explanation for why we don’t see as much cell
death. So there is some variability between cell lines in terms of
the induction of cell death. I chose to present the NCI-H226 cell
line particularly because it made a pretty good movie in terms of
demonstrating apoptotic cell death.
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